Biocon launches GLP-1 peptide, Liraglutide in the Netherlands
Under brand names Diavorin and Vobexoryn
WHO endorsement sparks new discussion around GLP-1 drugs and PCOS
The World Health Organization’s recent endorsement of GLP-1 medications, such as Ozempic, is prompting renewed discussion about their potential role in treating polycystic ovary syndrome (PCOS), a hormonal condition affecting millions. Canadian experts say the drugs may help address the metabolic dysfunction linked to PCOS, though more research is needed before they become standard care. […]
The New Diet Drugs vs. Exercise: Which Works Better?
The implications from the design of the clinical GLP-1 agonist trials and studies of caloric restriction are that exercise is basically irrelevant.
2 Predictions for Novo Nordisk in 2026
Key Points Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company’s pipeline candidates will see strong progress in 2026. Novo Nordisk’s shares appear attractive, despite the challenges it faces. 10 stocks we like better than Novo Nordisk › The past 18 months have […]
Chonky Kitties Beware: Ozempic for Cats Is on the Way
If your cat has reached a size best described as “majestically chonky,” science may soon have a solution that spares you from micromanaging every scoop. A weight-loss drug for cats, modeled after human medications like Ozempic, is now being tested in veterinary clinical trials. More than half of pet cats worldwide are estimated to be […]
Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy—a phase 2 randomized trial
Nature Communications, Published online: 14 December 2025; doi:10.1038/s41467-025-66167-z Semaglutide, a GLP-1 receptor agonist, may offer neuroprotective benefits after stroke, but its effects in large vessel occlusion (LVO) are unknown. Here the authors show, in a phase 2 randomized trial, that semaglutide is safe after endovascular therapy and may improve recovery in patients not receiving intravenous […]
COMMENTARY: The real story behind Trump’s GLP-1 price cut: Markets still rule
Price controls sap resources and ingenuity from America’s pharmaceutical sector
How Were GLP-1 Drugs and Bone Health Linked?
(MedPage Today) — You passed medical training, now see if you can pass our weekly quiz
“DPP- 4 inhibitor alleviates gut-brain axis Parkinsons disease pathology” – can dipeptidyl peptidase 4 inhibitors be repurposed as disease-modifying drugs for body-first Parkinsons disease patients?
In their manuscript, Jeong et al investigated the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4is), in a rotenone-based mouse model of Parkinson’s disease (PD).1 The study explored the association between diabetes and PD, focusing on the potential therapeutic benefits of glucagon-like peptide-1 receptor (GLP-1-R) agonists,2 given that DPP-4is are hypoglycaemic agents that enhance the […]
Ozempic may offer a surprising bonus benefit for brain health
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous […]